8-K ·Filed Sep 1, 2026

MTEX

MANNATECH INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed1mo ago SEC0001437749-26-029403
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine board succession filing with no financial or operational implications. Monitor next 10-Q for any strategic commentary from the new Chairman, but no immediate trading action is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
MTEX ▲ +5.28% at T+20d
NEUTRAL call ✓ call won +5.28% · α vs SPY +5.36% · entry $6.82 → $7.18
Next anchor: T+60d in 8w
Latest observation: T+21 -12.63% FF3 residual α
Entry anchored
Sep 1, 03:58 PM ET
via 1-min bar
T+1d
+6.89%
call +6.89% · α +5.84%
$7.29
settled 4w ago
T+5d
+24.78%
call +24.78% · α +25.74%
$8.51
settled 24d ago
T+20d
+5.28%
call +5.28% · α +5.36%
$7.18
settled 3d ago
T+60d
—
call — · α —
—
in 8w

Price Chart

Loading chart...

Executive Summary

Mannatech announced the retirement of Chairman J. Stanley Fredrick effective September 1, 2026, and the appointment of Vice Chairman Robert Toth as his successor. The transition is described as voluntary and amicable, with no disagreement cited. This is a routine governance change with no financial impact or strategic shift.

Key Facts

  • J. Stanley Fredrick retired from the Board and as Chairman effective September 1, 2026, for personal reasons.
  • Robert Toth was appointed Chairman of the Board effective September 1, 2026.
  • Toth will receive additional annual compensation of $50,000 plus a $50,000 equity component (deferred) in year one, and an additional $100,000 fee in years two and three.
  • Fredrick's director retainer will continue through December 31, 2026, to assist with the transition.

Financial Impact

No material financial impact. Chairman compensation changes are routine and immaterial relative to company size.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-029403
Exhibit: ex_1010181.htm0001437749-26-029403
Document: 0001437749-26-029403-index-headers.html0001437749-26-029403
Document: 0001437749-26-029403-index.html0001437749-26-029403
Document: 0001437749-26-029403.txt0001437749-26-029403
11 reports for MTEX
Performance horizon
100% Hit rate 7 of 7 directional calls best @ T+60▲ +58.23%May 20, 2026
Filters
Rows
Reports for MTEX — sortable, filterable
TypeNow
Sep 1, 2026
4w ago
8-K
NEUTRAL ★ 2/10
$6.82 $7.18▲ +5.28%▲ +5.36%$6.99 (+2.49%)
Aug 12, 2026
7w ago
8-K
BULLISH ★ 6/10
$6.15 $8.21▲ +33.50%▲ +35.24%$6.99 (+13.66%)
Aug 12, 2026
7w ago
Press Release
BULLISH ★ 6/10
$6.15 $8.21▲ +33.50%▲ +35.24%$6.99 (+13.66%)
Jun 8, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$5.59 $5.25▼ −6.08%▼ −7.53%$6.99 (+25.04%)
May 21, 2026
19w ago
Insider Cluster
MIXED ★ 5/10
$4.42 $5.40▲ +22.17%▲ +21.84%$6.99 (+58.14%)
May 20, 2026
19w ago
Insider Cluster
BULLISH ★ 6/10
$3.95 $5.42▲ +37.22%▲ +36.47%$6.99 (+76.96%)
May 14, 2026
20w ago
8-K
BEARISH ★ 6/10
$4.22 $5.65▼ −33.89%▼ −31.77%$6.99 (−65.64%)
Apr 24, 2026
23w ago
8-K
BEARISH ★ 8/10
$4.68 $5.53▼ −18.16%▼ −13.21%$6.99 (−49.36%)
Apr 21, 2026
23w ago
DEFA14A
NEUTRAL ★ 3/10
$4.86 $4.12▼ −15.23%▼ −20.14%$6.99 (+43.83%)
Apr 17, 2026
24w ago
Press Release
BEARISH ★ 8/10
$5.02 $4.12▲ +17.93%▲ +22.13%$6.99 (−39.24%)
Showing 10 of 11

US Market Status

Market Closed — Opens Mon (36h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access